Introduction
============

*Mycoplasma pneumoniae* is one of the most common pathogens causing community-acquired pneumonia in school-aged children and young adults \[[@b1-kjp-2018-07367]\]. The pathogenesis of *M. pneumoniae* infections results from direct epithelial damage or the host's immune response \[[@b2-kjp-2018-07367],[@b3-kjp-2018-07367]\]. The immunological response following infection generates inflammatory reactions that may cause pulmonary and extrapulmonary manifestations. *M. pneumoniae* attaches to epithelial surfaces in airways and releases toxic molecules (i.e., a pertussis toxin-like protein termed CARDS \[community-acquired respiratory distress syndrome\] toxin) \[[@b4-kjp-2018-07367]\], thereby inducing epithelial damage to acquire the nutrients for their growth \[[@b5-kjp-2018-07367]\].

Macrolides are the first-line treatments of *M. pneumoniae* pneumonia (MPP) mainly because of their low minimum inhibitory concentration (MIC) and because of their safety in young children. Recently, macrolide resistance has been rapidly rising worldwide, particularly in East Asia. Macrolide-resistant MPP (MRMP) first developed in Asia \[[@b6-kjp-2018-07367]\], where MRMP rates have increased to 90%--100% in China, 87% in Japan, and 84.6% in Korea \[[@b6-kjp-2018-07367]-[@b8-kjp-2018-07367]\]. MRMP has also recently been reported in North America and Europe, as high as 13% in the United States, 26% in Italy, and 19% in Scotland \[[@b5-kjp-2018-07367],[@b9-kjp-2018-07367]\]. The prevalence of MRMP in East Asia contrasts dramatically with that in reports from North America or Europe. The high macrolide resistance rates in Asia may be associated with antibiotic selective pressure resulting from extensive macrolide use \[[@b10-kjp-2018-07367]\]. This is supported by findings from Japan showing that the macrolide resistance rate was highest in areas with extensive macrolide use \[[@b11-kjp-2018-07367]\] and that it decreased by 43.6% in 2015 from its highest prevalence of 81.6% in 2012 along with a reduction in macrolide prescriptions \[[@b12-kjp-2018-07367]\].

MPP is usually a benign, self-remitting disease. However, it can cause extrapulmonary complications and progress to a severe life-threatening pneumonia. It has been thought that clinical symptoms, severity of pneumonia, and laboratory and radiographic findings were similar regardless of macrolide resistance \[[@b13-kjp-2018-07367]-[@b15-kjp-2018-07367]\]. Generally, acquisition of resistance does not increase the pathogen's virulence but may make treatment more difficult and lead to more complications with ineffective antimicrobial treatment \[[@b5-kjp-2018-07367]\]. Several studies have indicated that MRMP has been associated with a slower reduction in bacterial load, persistent clinical symptoms such as fever or cough, longer length of hospital stay, and higher rates of pneumonia progression and extrapulmonary complications during macrolide treatment and, thereby, high rates of antibiotic change \[[@b16-kjp-2018-07367]-[@b18-kjp-2018-07367]\]. In contrast, macrolides appear clinically effective in some patients infected by macrolide-resistant strains; approximately 30% of MRMP could be treated by macrolides \[[@b13-kjp-2018-07367],[@b14-kjp-2018-07367],[@b17-kjp-2018-07367]\]. This observation can be explained by the fact that MP infections are often self-limited diseases and that the anti-inflammatory effects of macrolides may improve clinical symptoms. Clinical manifestations, such as extrapulmonary complications or radiological deterioration rather than macrolide resistance, are important determinants of the clinical course \[[@b7-kjp-2018-07367]\]. Therefore, although macrolide resistance might not be a problem in mild cases, therapeutic alternatives might be warranted in severe cases.

Tetracyclines (TCs) and fluoroquinolones (FQs) are recommended as effective alternatives. However, using TCs in children under 8 years of age and FQs in children under 18 years of age are contraindicated by the Korean Food and Drug Administration and blocked by the Korean Drug Utilization Review system because of the potential adverse reactions such as tooth discoloration or tendinopathy. In addition, there are no clinical practice guidelines (CPGs) for treating MRMP in Korean children. Delaying decisions to use alternative antimicrobials may induce further complications of the disease itself, a poor quality of life, as well as a healthcare-related burden. Therefore, appropriate guidelines supporting clinical decision making need to be developed. This article aims to review the benefits and risks of therapeutic alternatives for treating MRMP in children and to summarize the recommendations of international or regional guidelines and specific considerations for their practical application.

Alternative antimicrobials: guideline recommendations
=====================================================

Since 2010, 4 CPGs have stated recommendations regarding alternative antimicrobials for treating MPP \[[@b1-kjp-2018-07367],[@b19-kjp-2018-07367]-[@b21-kjp-2018-07367]\], and only three CPGs state specific recommendations for treating MRMP \[[@b19-kjp-2018-07367]-[@b21-kjp-2018-07367]\].

• The guidelines of the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA) for the management of community-acquired pneumonia in infants and children older than 3 months, published in 2011 \[[@b1-kjp-2018-07367]\], recommend (1) azithromycin as a first-line drug for MPP and (2) doxycycline (for patients aged \>7 years) or levofloxacin/moxifloxacin (for adolescent patients with skeletal maturity) as second-line oral drugs and erythromycin or levofloxacin as second-line parenteral drugs for MPP. The PIDS and IDSA guidelines do not state specific recommendations for treating MRMP.

• The Guidelines for the Management of Respiratory Infectious Diseases in Children by the Japan Pediatric Society in 2011 \[[@b21-kjp-2018-07367]\] and the guiding principles of the Committee of the Japanese Society of Mycoplasmology in 2014 \[[@b19-kjp-2018-07367]\] state that (1) macrolides are recommended as the first-line drug of choice for treating MPP, (2) the efficacy of macrolides is assessed by the presence or absence of defervescence within 48--72 hours after initiation of macrolide treatment, and (3) use of tosufloxacin or TCs may be considered for persistent pneumonia that does not respond to macrolides; however, TCs are basically contraindicated in children under 8 years of age.

• The 2015 Hong Kong Practice Recommendation for Management of Community Acquired Pneumonia in Children \[[@b20-kjp-2018-07367]\] stated that physicians should consider MRMP if children with MPP fail to respond to macrolide therapy and recommended doxycycline for treating MRMP in children \>8 years of age and when the benefit exceeds the risk for children ≤8 years of age. Levofloxacin is an alternative option to doxycycline for MRMP in children aged ≤8 years. For severe MRMP cases where oral antibiotics cannot be tolerated, intravenous minocycline can be used (4 mg/kg/day on the first day, followed by 2 mg/kg every 12 hours for a maximum of 100 mg).

All of the guidelines' recommendations are not based on evidence but rather based on expert opinion. The first- and second-line antimicrobials and their dose and duration of use are summarized in [Table 1](#t1-kjp-2018-07367){ref-type="table"}.

Benefits and risks of alternative antimicrobials
================================================

The MICs of TCs and FQs against MP are relatively high compared with macrolides, and infection may persist in the airways and disseminate after treatment \[[@b22-kjp-2018-07367]\]. Therefore, macrolides are the first-line drug of choice for macrolide-sensitive MPP. However, TCs and FQs were shown to be more effective than macrolides in patients infected by MRMP \[[@b23-kjp-2018-07367]\]. The clinical benefit of TCs and FQs are shortening the duration of symptoms and rapid defervescence. Alternative antimicrobials may be considered when patients remain febrile or chest radiographs shows deterioration at 48--72 hours after macrolide treatment. Although no studies were designed to directly compare the efficacy of TCs and FQs in MRMP, Okada et al. \[[@b11-kjp-2018-07367]\] reported that minocycline or doxycycline was superior to tosufloxacin regarding improvement of clinical symptoms and reduction in the numbers of DNA copies. Morozumi et al. \[[@b24-kjp-2018-07367]\] showed that minocycline, doxycycline, and tosufloxacin showed excellent bactericidal activity, but the post-antibiotic effect was lower for tosufloxacin than for minocycline or doxycycline. However, only a few studies compared TCs with tosufloxacin among FQs, and no studies have compared other FQs. Therefore, there is still a limit to compare the effectiveness of TCs and FQs.

TC has been used since 1953, but in the early 1960s, dental side effects were associated with the use of TC. Children with cystic fibrosis who were treated with TC presented a high prevalence (23%--92%) of tooth discoloration in a dose- and age-dependent manner \[[@b25-kjp-2018-07367]-[@b28-kjp-2018-07367]\].

Doxycycline is a second-generation TC with a broad therapeutic spectrum (Rocky Mountain spotted fever \[RMSF\] \[[@b29-kjp-2018-07367]\], Q fever \[[@b30-kjp-2018-07367]\], malaria \[[@b31-kjp-2018-07367]\], and community-acquired pneumonia \[[@b32-kjp-2018-07367]\]) that rarely causes adverse events \[[@b33-kjp-2018-07367]\]. It has a lower binding affinity to calcium than TC, leading to a reduced risk of tooth discoloration and enamel hypoplasia \[[@b34-kjp-2018-07367],[@b35-kjp-2018-07367]\]. Doxycycline treatment at 4 mg/kg/day for 10 days in children aged 2--7 years with asthma \[[@b32-kjp-2018-07367]\], 2.3 mg/kg/day for 7 days in children aged 0.2--7.9 years with RMSF \[[@b29-kjp-2018-07367]\], and 10 mg/kg/day for 12.5 days in children \<8 years of age with CNS infections \[[@b36-kjp-2018-07367]\] did not induce staining of permanent teeth. There was only one reported case of slightly spotted discoloration of one deciduous tooth after doxycycline use in a prematurely born infants \<2 months of age \[[@b34-kjp-2018-07367]\]. Contrary to TC, tooth discoloration was not associated with the duration of doxycycline-use \[[@b29-kjp-2018-07367]\]. However, discoloration of teeth was observed (2.8%) in adults receiving prolonged courses of doxycycline (100 mg twice daily for 6 months) for abdominal aortic aneurysms \[[@b37-kjp-2018-07367]\]. Since 2013, the U.S. Centers for Disease Control and Prevention (CDC) have recommended the use of doxycycline at a dose of 2.2 mg/kg twice daily for 2 weeks in children \<8 years of age for treating acute and chronic Q fever in the United States \[[@b33-kjp-2018-07367]\]. The CDC Rickettsial Zoonoses Branch recommends doxycycline for treating tick-borne rickettsial diseases, which continue to cause severe illness and death in otherwise healthy adults and children in the United States in 2016 \[[@b38-kjp-2018-07367]\]. Doxycycline is recommended as a first-line drug when benefits exceed risks.

The FQs are generally well tolerated, but they damage cartilage in the weight-bearing joints of juvenile animals \[[@b39-kjp-2018-07367]\]. FQ-induced tendinopathy preferentially occurs in adolescents during their pubertal growth spurt following long-term treatment \[[@b40-kjp-2018-07367]\]. Achilles tendon injuries associated with FQs have been well recognized with an incidence of 0.08%--2.0% \[[@b41-kjp-2018-07367]\]. The U.S. Food and Drug Administration has directed manufacturers of FQs to warn doctors and patients about the increased risk of tendinitis and tender rupture as a "black box" warning \[[@b42-kjp-2018-07367]\]. They have highlighted restricting FQ use to patients with complicated infections and patients for whom there is no suitable alternative antibiotic because of the risk of tendinopathy and other adverse events such as peripheral neuropathy and worsening of myasthenia gravis \[[@b43-kjp-2018-07367]\].

The Levaquin Pediatric Program, a randomized controlled trial that assessed the efficacy and safety of levofloxacin in children in 1998, reported that the incidence of musculoskeletal disorders (arthralgia, arthritis, gait abnormality, or tendinopathy) was higher in levofloxacin-treated children than in children treated with non-FQ therapy (odds ratio \[OR\], 2.4; 95% confidence interval \[CI\], 1.1--5.2 at 2 months; OR, 1.9; 95% CI, 1.1--3.5 at 1 year) \[[@b44-kjp-2018-07367]\]. These disorders were typically transient, and all resolved without apparent sequelae over the 1-year period of observation.

The risk of Achilles tendon rupture seemed to be highest in the first month after exposure \[[@b45-kjp-2018-07367]-[@b47-kjp-2018-07367]\]. A systematic review regarding ciprofloxacin safety in pediatric patients (105 studies published between 1950 and 2009, including 16,184 pediatric patients aged ≤17 years) has concluded that the most frequent adverse event of ciprofloxacin was arthropathy; it showed a 57% increased risk, which appeared reversible with management \[[@b48-kjp-2018-07367]\]. Tendon rupture is also a well-known complication associated with FQs in adult patients of advanced age, with preceding steroid use, and with underlying diseases, but there are no reports in children to date \[[@b49-kjp-2018-07367]\]. Taken together, the incidence of FQ-related tendinopathy is negligible, but some of the underlying diseases and concurrent use of corticosteroids may increase the risk or tendinopathy.

Systemic corticosteroids: guideline recommendations
===================================================

Patients with MRMP showed higher levels of inflammatory cytokines than patients infected with macrolide-sensitive MPP \[[@b50-kjp-2018-07367],[@b51-kjp-2018-07367]\]. These findings suggest that persistent inflammatory stimulation by MRMP may increase the possibility of severe lung lesions and extrapulmonary complications. The pathophysiology of MPP is mainly associated with the host immune reaction. The efficacy of antibiotics for treating MPP was still controversial \[[@b52-kjp-2018-07367]\]. As an alternative, to reduce inflammation, systemic corticosteroids have been used. Only one guideline stated a specific recommendation for using systemic corticosteroids for treating MRMP in children. The Japanese guideline \[[@b19-kjp-2018-07367]\] recommended that systemic corticosteroids should be considered for children with serious pneumonia who do not respond to optimal antimicrobial therapy (≤15 years of age) and for patients with respiratory failure (≥16 years of age) but should not be used in patients who have no clear diagnosis or have not undergone appropriate antimicrobial therapy. Unfortunately, there has been only one randomized controlled trial reporting the effectiveness of corticosteroid add-on therapy \[[@b53-kjp-2018-07367]\]. There is no study comparing corticosteroids and alternative antimicrobials for treating childhood MRMP. Further studies should be conducted to prove the comparative effectiveness and to establish criteria for systemic corticosteroid treatment and optimal methods of administering corticosteroids. The benefits and risks of therapeutic alternatives are summarized in [Table 2](#t2-kjp-2018-07367){ref-type="table"}.

Specific considerations on the use of therapeutic alternatives
==============================================================

Intrinsic permanent tooth discoloration may also be resolved by vital bleaching with H~2~O~2~ and composite/porcelain veneers/crowns, and extrinsic tooth discoloration was suggested to be prevented by improving oral hygiene and avoiding sunlight during therapy or taking vitamin C \[[@b54-kjp-2018-07367],[@b55-kjp-2018-07367]\]. Particularly, adverse reactions are more common with minocycline (3%--6% of adult patients), mainly by an extrinsic pathway \[[@b56-kjp-2018-07367]\]. Therefore, a recent systematic review suggested minocycline as alternatives when doxycycline is unavailable \[[@b57-kjp-2018-07367]\]. TC-induced tooth discoloration may be induced by an intrinsic pathway when used in pregnant women or children \<8 years of age and also by an extrinsic pathway involving the formation of insoluble TC-calcium orthophosphate complexes that are deposited in dentine and enamel and darken upon exposure to light, even in adults \[[@b54-kjp-2018-07367],[@b55-kjp-2018-07367],[@b58-kjp-2018-07367],[@b59-kjp-2018-07367]\]. It has been suggested that strict avoidance of sunlight exposure during high-dose, long-term doxycycline therapy can prevent tooth complication \[[@b54-kjp-2018-07367]\].

FQ-induced tendinopathy is distinguished from other forms of tendinopathy by its abrupt onset and sharp pain that occurs spontaneously. The cardinal sign of tendinopathy is sudden onset and sharp pain that occurs spontaneously on movement or at rest \[[@b60-kjp-2018-07367]\]. Clinicians should pay attention to joint pain and switch to alternative treatments when joint pain occurs during FQ use, which should be ceased immediately when tendinopathy is suspected \[[@b43-kjp-2018-07367]\].

In Japan, the incidence of MRMP varies both regionally and epidemically, ranging from \<50% in patients with no history of macrolide treatment to \>90% in patients who were treated by macrolides without clinical effectiveness \[[@b8-kjp-2018-07367]\]. Furthermore, the prevalence of MRMP decreased in accord with a decrease in macrolide prescriptions in Japan \[[@b12-kjp-2018-07367]\], suggesting that the appropriate use of antimicrobials is essential to control the emerging MRMP.

To date, there is no report on naturally occurring resistance to TCs or FQs against *M. pneumoniae*. However, resistance to FQs has been reported in urogenital mycoplasmas \[[@b61-kjp-2018-07367]\], and in vitro studies have reported resistance for both drugs \[[@b62-kjp-2018-07367],[@b63-kjp-2018-07367]\]. In addition, TCs and FQs have a broad antimicrobial spectrum and thereby may promote drug resistance of nontargeted microorganisms. The use of doxycycline for malaria chemoprophylaxis could raise the risk of selecting bacterial pathogens resistant to antibiotics \[[@b64-kjp-2018-07367]\]. Particularly, the emergence of FQ-resistant *Mycobacterium tuberculosis* could lead to devastating consequences. Therefore, clinicians should pay attention to the emergence of resistance to these antimicrobials as well as their optimal dose and duration.

Conclusions
===========

The benefits of therapeutic alternatives obviously outweigh the risks of their adverse outcomes in children with severe MRMP. The initial severity and disease progression rather than only the persistence of fever should be considered in the use of therapeutic alternatives. The role of alternative antimicrobials and systemic corticosteroids is quite different. Systemic corticosteroids should be considered to reduce inflammation in severe intra- or extrapulmonary manifestations. Alternative antimicrobials should be limited to treating MRMP to reduce the bacterial load. Because concurrent use of systemic corticosteroids and FQs might increase the risk of tendinopathy, clinicians should avoid this combination. Taken together, clinicians should consider using therapeutic alternatives when benefits outweigh the risks in MRMP and should be aware of specific considerations for each alternative.
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###### 

Recommended first-line and second-line antimicrobials in the treatment of MRMP in children, optimal doses, and duration of use

  Country            Line                        Drug           Route of administration   Dose (mg/kg/day)                              Duration of treatment (day)   Notice
  ------------------ --------------------------- -------------- ------------------------- --------------------------------------------- ----------------------------- ------------------
  Japan \[19,21\]    First-line                  Erythromycin   Oral                      25--50                                        14                            
  Clarithromycin     Oral                        10--15         10                                                                                                    
  Azithromycin       Oral                        10             3                                                                                                     
  Second-line        Tosufloxacin                Oral           12                        7--14                                         ≤8 years of age               
  Minocycline        Oral of IV                  2--4           7--14                                                                                                 
  Hong Kong \[20\]   Second-line                 Doxycycline    Oral                      4                                             Not mentioned                 \>8 years of age
  Levofloxacin       Oral                        8              Not mentioned             ≤8 years of age                                                             
  Minocycline        IV                          4              Not mentioned             When not tolerable oral medicine                                            
  USA \[1\]          First-line                  Azithromycin   Oral                      10 on day 1, and followed by 5 on days 2--5   5                             
                                                 Oral           15                        Not mentioned                                                               
                     Clarithromycin              Oral           40                        Not mentioned                                                               
                     Erythromycin                IV             10 on days 1--2           Not mentioned                                                               
                     Azithromycin                IV             20                        Not mentioned                                                               
                     Erythromycin lactobionate   Oral           24                        Not mentioned                                 \>7 years of age              
                     Second-line                 Doxycycline    Oral                      500 mg/day                                    Not mentioned                 Adolescents
                     Levofloxacin                IV             16--20                    Not mentioned                                 Adolescents                   
                     Moxifloxacin                Oral           400 mg/day                Not mentioned                                 Adolescents                   

MRMP, macrolide-resistant *Mycoplasma pneumoniae* pneumonia; IV, intravenous.

###### 

Benefits, risks, and specific consideration of therapeutic alternatives in the treatment of MRMP in children

  Category                                                                       Drug                                                                                                                                     Benefits                                                Risks                                                                          Specific consideration
  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------ -----------------------------------------------------------------------------------
  Tetracyclines                                                                  Tetracycline                                                                                                                             Shortening duration of                                  Tooth discoloration (23%--92%)                                                 1\) Safety: Doxycycline \> minocycline \> tetracycline
  Doxycycline                                                                    symptoms and rapid                                                                                                                       Tooth discoloration; only 1 case under usual dose       2\) short course with appropriate dose may be safe                             
  Minocycline                                                                    defervescence                                                                                                                            Adult-onset tooth (3%--6%), sclera, skin pigmentation   3\) Improving oral hygiene and avoidance of sunlight-exposure during therapy   
  4\) Concerns about resistance for nontargeted microorganisms                                                                                                                                                                                                                                                                                                   
  Fluoroquinolones                                                               Levofloxacin                                                                                                                                                                                     Achilles tendinopathy (0.08%--2.0%)                                            1\) Safety: no comparative study among fluoroquinolones
  Tosufloxacin                                                                   No available report                                                                                                                      2\) Resistance for urogenital mycoplasma                                                                                               
  3\) Specific concern for the development of FQs resistant *M. Tuberculosis.*                                                                                                                                                                                                                                                                                   
  Systemic corticosteroids                                                                                                                                                                                                Anti-inflammatory effect                                No available data for safety                                                   1\) The risk of systemic corticosteroids would not exceed the general, known risk
  No protocol for dose and duration                                              2\) It cannot reduce bacterial load. Just, it should be consider- ed for the purpose to reduce intra- or extrapulmonary inflammations.                                                                                                                                          
  3\) Concurrent use with fluoroquinolones may increase a risk of tendinopathy                                                                                                                                                                                                                                                                                   

MRMP, macrolide-resistant *Mycoplasma pneumoniae* pneumonia.
